Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value
40
Zitationen
8
Autoren
2016
Jahr
Abstract
The "big data" era represents an exciting opportunity to utilize powerful new sources of information to reduce clinical and health economic uncertainty on an individual patient level. In turn, health economic outcomes research (HEOR) practices will need to evolve to accommodate individual patient-level HEOR analyses. We propose the concept of "precision HEOR", which utilizes a combination of costs and outcomes derived from big data to inform healthcare decision-making that is tailored to highly specific patient clusters or individuals. To explore this concept, we discuss the current and future roles of HEOR in health sector decision-making, big data and predictive analytics, and several key HEOR contexts in which big data and predictive analytics might transform traditional HEOR into precision HEOR. The guidance document addresses issues related to the transition from traditional to precision HEOR practices, the evaluation of patient similarity analysis and its appropriateness for precision HEOR analysis, and future challenges to precision HEOR adoption. Precision HEOR should make precision medicine more realizable by aiding and adapting healthcare resource allocation. The combined hopes for precision medicine and precision HEOR are that individual patients receive the best possible medical care while overall healthcare costs remain manageable or become more cost-efficient.
Ähnliche Arbeiten
Meta-analysis in clinical trials
1986 · 38.761 Zit.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 · 37.555 Zit.
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
2018 · 37.235 Zit.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 · 33.490 Zit.
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · 28.405 Zit.